Indolent B Cell Lymphoma - 25 Studies Found
| Completed |
: Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas :
: 2016-02-25 :
|
| Completed |
: High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas :
: 2009-05-06 : Drug: rituximab Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosi |
| Completed |
: Indolent Non Follicular Lymphomas Prognostic Project : Indolent B-Cell Lymphomas : 2016-09-06 : Other: Any treatment, watch and wait policy included Patients registered in the study despite their plan |
| Completed |
: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers :
: Drug: Ibrutinib Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (l |
| Active, not recruiting |
: Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma :
|
| Completed |
: Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma : Lymphoma : 2015-07-08 : Radiation: Radiation Therapy Participants receive radiation to entire involved orbit for a total dose of |
| Recruiting |
: Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma :
|
| Completed |
: VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma :
: 2004-06-11 : Drug: VELCADE and rituximab |
| Withdrawn |
: Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas :
|
| Not yet recruiting |
: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma :
: 2016-09-08 :
|